Platform Protocol to Assess Treatments for Painful Diabetic Peripheral Neuropathy
Assess Treatments for Painful Diabetic Peripheral Neuropathy (PDPN)
Sponsor: Massachusetts General Hospital
Enrolling: Male and Female Patients
IRB Number: AAAU2206
U.S. Govt. ID: NCT05476276
Contact: Jorge Cabrera, CRC: 212-305-6035 / jec2273@cumc.columbia.edu
Additional Study Information: The purpose of this study is to Assess Treatments for Painful Diabetic Peripheral Neuropathy (PDPN). To be in this study you must have type II Diabetes Mellitus, PDPN, must be 18 years of age or older, and be able to stop taking some of your current pain medications including pills, creams, patches, marijuana, cannabidiol (CBD) oil, etc. Acetaminophen (commonly known as Tylenol) is the only allowable pain medication other than the study drug.
Investigator
Thomas Brannagan, MD
Do You Qualify?
Are you 18 years of age and older? Yes No
Are you diagnosed with Type II diabetes mellitus with painful diabetic peripheral neuropathy? Yes No
Are you on a stable treatment of diabetes for at least 3 months with no anticipated changes in medication regimen? Yes No
Are you willing and able to comply with scheduled visits? Yes No
Are you able to provide informed consent? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Jorge Cabrera, CRC
jec2273@cumc.columbia.edu
212-305-6035